Conference abstract · 21 Mar 2018
Conference abstractPublished 21 Mar 2018
ITP, IVIG and I
Kyungpook National University School of Medicine, Republic of Korea
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The main reason for intravenous immunoglobulin G (IVIG) treatment in acute phase of immune thrombocytopenic purpura (ITP) is prevention of possible life-threatening hemorrhage since 1981. On the 1st trial, I just followed the dose of 400 mg/kg/d of IVIG for 5 days for 8 patients with good result in 1983-1984 (Korean J Pediatr. 28:483-491, 1985). On the 2nd, I stopped medication when platelet was over 100,000 /Ã?¼L for 73 in 1985-1993. Mean treatment days were 2.8 days. The relapse and chronic ITP was less developed in rapid responders (RR: 1-3 treatment days) than in slow responders (SR: more than 3 days) (P<0.05) (Korean J Hematol 2001;36:241-6). On the 3rd, I also stopped medication when the platelet was over 50,000 /Ã?¼L for 68 in 1993-2001. Mean treatment days were 2.9 days. Seven of 28 RR and 6 of 8 SR were chronic type (p=0.016) (Korean J Hematol 2001;36:247-52). On the 4th, I reduced daily dose to 200 mg/kg/d when the platelet was over 50,000/Ã?¼L for 26 in 20052006. Average 2 days treatment were needed to increase the platelet count 50,000/Ã?¼L. Although all 10 non re-treat group who were follow-up over 6 months were acute, all 3 re-treat group who were follow-up over 6 months were chronic (p<0.003) (Clin Pediatr Hematol Oncol 2006;13:143-9). No one died with 4 studies. The IVIG dose was different according to one’s clinical response. In some patient only 1/10 of usual doses (2 g/kg) were sufficient to reach a safe platelet counts in usual life.
Subjects
Paediatrics & NeonatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Immunomodulation by biologic Intravenous immunoglobulins IVIG: immune thrombocytopenia ITP as a model for the last 30 Years
Conference abstract · 18 May 2015
A clinic epidemiological study of children with ITP: Single center experience
Research article · 7 Sep 2021
Prediction of Resistant to Intravenous Immunoglobulin (IVIG) Treatment in Patients with Kawasaki Disease in the Tertiary Care Hospital
Case report · 2013
Atypical HUS with Dysphagia and Palatal Palsy Responding to IVIG
More from this journal
The newest in Pediatrics & Therapeutics.
Conference abstract · 6 Oct 2025
Positive outcome in a patient with hypoplastic left heart syndrome: Key factors for successful survival: A case report
Conference abstract · 6 Oct 2025
Out of Hospital Neonatal Outcomes (OHNO) registry
Conference abstract · 6 Oct 2025
Innovations in Early Diagnosis of Neonatal Sepsis: Advances in Biomarkers and Clinical Protocols
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPediatrics & Therapeutics
- SubjectPaediatrics & Neonatology
- BylineArticles whose byline prints “Kun Soo Lee”

